Laura Alder, MD

Dr. Nagpal presents a 58-year-old female non-smoker with stage IVB lung adenocarcinoma, EGFR L858R mutation, and TP53 co-mutation who maintained partial systemic response on first-line osimertinib for approximately 3.5 years.

Dr. Alder raises the inconsistency of CNS surveillance across practice settings in EGFR-mutated NSCLC, noting that even within the FLAURA2 and MARIPOSA trials, brain MRI schedules were not uniform. She asks Dr. Nagpal to address evidence-based surveillance recommendations and the barriers to implementing them.

Dr. Nagpal reviews frontline CNS data from the FLAURA2 and MARIPOSA trials, noting the importance of CNS-specific endpoints now being routinely incorporated into NSCLC clinical trials. Both trials enrolled patients with stable, predominantly pre-treated brain metastases.

Samuel Rosner, MD, and Laura Alder, MD, discuss ongoing research to watch in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss AE management and compliance strategies for patients with EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss how antibody-drug conjugates have affected the EGFR-mutated NSCLC treatment paradigm.

Samuel Rosner, MD, and Laura Alder, MD, discuss treatment approaches following frontline use of the MARIPOSA or FLAURA-2 regimens in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss how MET status and other factors can help inform sequencing decisions in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss combination vs monotherapy approaches in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss factors that help inform frontline treatment selection in EGFR-mutated NSCLC.

Laura Alder, MD, discusses clinical decision-making around prioritizing local vs systemic therapy for patients with lung cancer who present with CNS-only metastatic disease.